



National Imaging Associates, Inc.*	
Clinical guideline STEREOTACTIC RADIOTHERAPY (SRS) STEREOTACTIC BODY RADIATION THERAPY (SBRT)	Original Date: May 2011
CPT Codes: 77371, 77372, 77373, G0339, G0340	Last Revised Date: January 2022
Guideline Number: NIA_CG_222	Implementation Date: January 2023

Stereotactic radiation therapy (SRT) is a method of delivering precise high doses of radiation to small targets, while minimizing radiation-related injury in adjacent normal tissues.^{1, 2} SRT delivers high doses of radiation in a very short time frame as, between 1 and 5 fractions (entire course not to exceed 5 fractions) and consists of the following types¹:

- Stereotactic Body Radiotherapy (SBRT) refers to use at any extracranial site consisting of 2-5 fractions
- Stereotactic Cranial Radiotherapy consisting of 2-5 fractions to use at any intracranial site
- Stereotactic radiosurgery (SRS) refers to treatment of any intracranial site consisting of 1 fraction only.

INDICATIONS FOR STEREOTACTIC RADIATION THERAPY

Most requests for radiation therapy are addressed by NIA treatment site clinical guidelines. However, there may be requests that are not. For such requests, determinations will be made on a case-by-case basis utilizing the following guidelines (when applicable) but not limited to: National Comprehensive Cancer Network (NCCN), American Society for Radiation Oncology ASTRO (i.e., Model Policies; Evidence-Based Consensus Statement), ACR Appropriateness Criteria, American Society of Clinical Oncology (ASCO) and/or peer reviewed literature.

- Arteriovenous malformation (AVM) of the brain or spine¹
- Initial or recurrent primary brain tumor (e.g., acoustic neuroma, meningioma, hemangioma, pituitary adenoma, craniopharyngioma, low grade glioma, neoplasm of the pineal gland, glioblastoma multiforme, low-grade astrocytoma, etc.)¹
- Initial or recurrent brain metastases for patient who has good performance status (ECOG less than 3 or Karnofsky status 40 or greater with expected return to 70 or greater with treatment) and controlled systemic disease (e.g., newly diagnosed, stable systemic disease or reasonable treatment options).¹ Refer to the clinical guideline on Central Nervous System (CNS) metastasis

* National Imaging Associates, Inc. (NIA) is a subsidiary of Evolent Health LLC.

1—SRS –SBRT Rad Onc

© 2019-2022 National Imaging Associates, Inc., All Rights Reserved

- Non-operable spinal tumor (primary, recurrent or metastatic) that is causing compression or intractable pain
- Trigeminal neuralgia that has not responded to other, more conservative, treatments¹
- Non-Small Cell Lung Cancer and all of the following³:
 - Stage I disease; **AND**
 - The lesion cannot be removed surgically either because the tumor location makes removal difficult, the member is not a surgical candidate, or if the patient refuses surgery
- Small Cell Lung Cancer⁴⁻¹²
 - SBRT is approvable for clinical stage I to IIA (T1-2,N0) Small Cell Lung Cancer who are medically inoperable or refuse surgery.

PHYSICIAN CLINICAL REVIEW REQUIRED

- Stereotactic Radiation Therapy (SRS/SBRT) has not been proven to be superior to conventional therapy and is not a standard treatment option for the treatment of the following conditions:
 - Other non-central nervous system cancers unless noted above
 - Lung (unless above criteria is met)
 - Other cancers, including but not limited to, breast, colon, liver and pancreas
 - Parkinson's disease and other movement disorders (e.g., tremors)
 - Epilepsy
 - Chronic pain syndromes
 - Treatment of functional disorders other than trigeminal neuralgia
- Pancreatic Tumors¹³: SBRT is appropriate for pancreatic cancer to treat locally advanced or recurrent disease without evidence of distant metastasis **or** to treat a previously irradiated field
- **Oligometastatic Disease¹⁴**
 - Stereotactic Body Radiation Therapy (SBRT) is medically necessary for extracranial oligometastatic disease for an individual with One (1) to Five (5) metastatic lesions when the following criteria are met:
 - Good performance status: ECOG less than 3 or Karnofsky Scale greater than or equal to 70% and stable systemic disease or reasonable systemic treatment options.
- SBRT may be appropriate for patients with tumors arising in or near previously irradiated region to minimize the risk of injury to surrounding normal tissues (Physician Review Required)¹

POLICY HISTORY

Date	Summary
January 2022	<ul style="list-style-type: none"> Added SCLC: SBRT is approvable for clinical stage I to IIA (T1-2, N0) SCLC who are medically inoperable or refuse surgery Clarified “Good performance status” under Oligometastatic disease Under Oligometastatic disease, increased range of metastatic lesions to 1 – 5 (previously 1 – 4)
February 2021	<p>Deleted: Stereotactic Body Radiation Therapy (SBRT) is considered medically necessary for the treatment of pancreatic cancer. If requested a physician review is required.</p> <p>Updated: Pancreatic Tumors (NCCN, 2019) SBRT is appropriate for pancreatic cancer to treat locally advanced or recurrent disease without evidence of distant metastasis or to treat a previously irradiated field (Physician Review Required)</p> <p>Added</p> <ul style="list-style-type: none"> Oligometastatic Disease: Stereotactic Body Radiation Therapy (SBRT) is medically necessary for extracranial oligometastatic disease for an individual with One (1) to Four (4) metastatic lesions when the following criteria are met: (Cheung P, 2016; Palma 2018) <ul style="list-style-type: none"> Good performance status: ECOG less than 3 or Karnofsky Scale greater than or equal to 70% and Stable systemic disease or reasonable systemic treatment options. <p>3. Added References</p>
February 2020	<ul style="list-style-type: none"> Guideline updated to state that SBRT is medically necessary for pancreatic tumors and patients with tumors previously irradiated, Based on NCCN Guideline Updates <ul style="list-style-type: none"> Added: Pancreatic Tumors (Physician Review Required) Added: SBRT may be appropriate for patients with tumors arising in or near previously irradiated region to minimize the risk of injury to surrounding normal tissues (Physician Review Required)
February 2019	<ul style="list-style-type: none"> Added and updated references

REFERENCES

1. American Society for Radiation Oncology. Model Policies: Stereotactic Body Radiation Therapy. American Society for Radiation Oncology (ASTRO). Updated June 2020. Accessed December 7, 2021. <https://www.astro.org/ASTRO/media/ASTRO/Daily%20Practice/PDFs/ASTROSBRTModelPolicy.pdf>
2. American College of Radiology, American, Society for Radiation Oncology, . ACR-ASTRO Practice Parameter for the Performance of Stereotactic Body Radiation Therapy. Updated 2019. Accessed November 9, 2021. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/SBRT-RO.pdf>
3. Videtic GMM, Donington J, Giuliani M, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. *Pract Radiat Oncol*. Sep-Oct 2017;7(5):295-301. doi:10.1016/j.prro.2017.04.014
4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Small Cell Lung Cancer Version 2.2022. National Comprehensive Cancer Network (NCCN). Updated November 24, 2021. Accessed December 7, 2021. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
5. Shioyama Y, Onishi H, Takayama K, et al. Clinical Outcomes of Stereotactic Body Radiotherapy for Patients With Stage I Small-Cell Lung Cancer: Analysis of a Subset of the Japanese Radiological Society Multi-Institutional SBRT Study Group Database. *Technol Cancer Res Treat*. Jan 1 2018;17:1533033818783904. doi:10.1177/1533033818783904
6. Videtic GM, Stephans KL, Woody NM, et al. Stereotactic body radiation therapy-based treatment model for stage I medically inoperable small cell lung cancer. *Pract Radiat Oncol*. Oct-Dec 2013;3(4):301-6. doi:10.1016/j.prro.2012.10.003
7. Verma V, Simone CB, 2nd, Allen PK, et al. Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys*. Feb 1 2017;97(2):362-371. doi:10.1016/j.ijrobp.2016.10.041
8. Alongi F, Arcangeli S, De Bari B, et al. Stage-I small cell lung cancer: A new potential option for stereotactic ablative radiation therapy? A review of literature. *Crit Rev Oncol Hematol*. Apr 2017;112:67-71. doi:10.1016/j.critrevonc.2017.02.010
9. Rathod S, Koul R, Bashir B, Chowdhury A, Dubey A. Role of Stereotactic Body Radiation Therapy in Early Stage Small Cell Lung Cancer in the Era of Lung Cancer Screening: A Systematic Review. *Am J Clin Oncol*. Feb 2019;42(2):123-130. doi:10.1097/coc.0000000000000489
10. Shioyama Y, Nakamura K, Sasaki T, et al. Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience. *J Radiat Res*. Jan 2013;54(1):108-12. doi:10.1093/jrr/rrs075
11. Li C, Xiong Y, Zhou Z, et al. Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study. *Med Oncol*. Dec 2014;31(12):369. doi:10.1007/s12032-014-0369-x
12. Verma V, Simone CB, 2nd, Allen PK, Lin SH. Outcomes of Stereotactic Body Radiotherapy for T1-T2N0 Small Cell Carcinoma According to Addition of Chemotherapy and Prophylactic Cranial Irradiation: A Multicenter Analysis. *Clin Lung Cancer*. Nov 2017;18(6):675-681.e1. doi:10.1016/j.clc.2017.03.009
13. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Pancreatic Adenocarcinoma Version 1.2019. National Comprehensive Cancer Network (NCCN). Accessed February 20, 2020. https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf

14. Lievens Y, Guckenberger M, Gomez D, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. *Radiother Oncol*. Jul 2020;148:157-166. doi:10.1016/j.radonc.2020.04.003

ADDITIONAL RESOURCES

1. Alongi F, Arcangeli S, Filippi AR, Ricardi U, Scorsetti M. Review and uses of stereotactic body radiation therapy for oligometastases. *Oncologist*. 2012;17(8):1100-7. doi:10.1634/theoncologist.2012-0092
2. American College of Radiology, . ACR Practice Parameter for the Performance of Brain Stereotactic Radiosurgery. Updated 2021. Accessed November 9, 2021. <https://www.acr.org/-/media/ACR/Files/Practice-Parameters/StereoBrain.pdf>
3. American Society for Radiation Oncology, . High doses of stereotactic body radiotherapy for patients with organ-confined prostate cancer shows high relapse-free survival. Updated October 30, 2012. Accessed December 7, 2021. https://www.astro.org/uploadedFiles/Main_Site/News_and_Media/Media_Resources/Press_Kits/Annual_Meeting_2012/ASTRO%20Annual%20Meeting%20RIs%20-%20KatzA%20FINAL.pdf
4. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. *Jama*. Jun 7 2006;295(21):2483-91. doi:10.1001/jama.295.21.2483
5. Bernard B, Gershman B, Karnes RJ, Sweeney CJ, Vapiwala N. Approach to Oligometastatic Prostate Cancer. *Am Soc Clin Oncol Educ Book*. 2016;35:119-29. doi:10.1200/edbk_159241
6. Bhattasali O, Chen LN, Woo J, et al. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer. *Radiat Oncol*. Feb 11 2014;9:52. doi:10.1186/1748-717x-9-52
7. Chang BK, Timmerman RD. Stereotactic body radiation therapy: a comprehensive review. *Am J Clin Oncol*. Dec 2007;30(6):637-44. doi:10.1097/COC.0b013e3180ca7cb1
8. Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. *Cancer*. Sep 1 2011;117(17):4060-9. doi:10.1002/cncr.25997
9. Chen LN, Suy S, Uhm S, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. *Radiat Oncol*. Mar 13 2013;8:58. doi:10.1186/1748-717x-8-58
10. Degen JW, Gagnon GJ, Voyadzis JM, et al. CyberKnife stereotactic radiosurgical treatment of spinal tumors for pain control and quality of life. *J Neurosurg Spine*. May 2005;2(5):540-9. doi:10.3171/spi.2005.2.5.0540
11. Cheung P. Stereotactic body radiotherapy for oligoprogressive cancer. *Br J Radiol*. Oct 2016;89(1066):20160251. doi:10.1259/bjr.20160251
12. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. *J Clin Oncol*. Apr 10 2013;31(11):1384-90. doi:10.1200/jco.2012.45.9651
13. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. *Radiat Oncol*. Jan 10 2011;6:3. doi:10.1186/1748-717x-6-3

14. Henzel M, Gross MW, Hamm K, et al. Significant tumor volume reduction of meningiomas after stereotactic radiotherapy: results of a prospective multicenter study. *Neurosurgery*. Dec 2006;59(6):1188-94; discussion 1194. doi:10.1227/01.Neu.0000245626.93215.F6
15. Jabbari S, Weinberg VK, Kaprealian T, et al. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. *Int J Radiat Oncol Biol Phys*. Jan 1 2012;82(1):228-34. doi:10.1016/j.ijrobp.2010.10.026
16. Ju AW, Wang H, Oermann EK, et al. Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer. *Radiat Oncol*. Jan 31 2013;8:30. doi:10.1186/1748-717x-8-30
17. Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. *Radiat Oncol*. May 13 2013;8:118. doi:10.1186/1748-717x-8-118
18. Katz A, Ferrer M, Suárez JF. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer. *Radiat Oncol*. Nov 20 2012;7:194. doi:10.1186/1748-717x-7-194
19. Kong DS, Lee JI, Lim DH, et al. The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution. *Cancer*. Aug 15 2007;110(4):854-60. doi:10.1002/cncr.22860
20. Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. Mar 1 2008;70(3):685-92. doi:10.1016/j.ijrobp.2007.10.053
21. Lunsford LD, Niranjan A, Flickinger JC, Maitz A, Kondziolka D. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. *J Neurosurg*. Jan 2005;102 Suppl:195-9.
22. McBride SM, Wong DS, Dombrowski JJ, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. *Cancer*. Aug 1 2012;118(15):3681-90. doi:10.1002/cncr.26699
23. McClelland S, 3rd, Gerbi BJ, Higgins PD, Orner JB, Hall WA. Safety and efficacy of fractionated stereotactic radiotherapy for acoustic neuromas. *J Neurooncol*. Jan 2008;86(2):191-4. doi:10.1007/s11060-007-9456-6
24. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Non-Small Cell Lung Cancer Version 7.2021. National Comprehensive Cancer Network (NCCN). Updated October 29, 2021. Accessed December 6, 2021. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
25. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Prostate Cancer Version 2.2022. National Comprehensive Cancer Network (NCCN). Updated November 30, 2021. Accessed December 7, 2021. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
26. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Melanoma: Uveal Version 2.2021. National Comprehensive Cancer Network (NCCN). Updated June 25, 2021. Accessed December 7, 2021. https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf
27. Oermann EK, Suy S, Hanscom HN, et al. Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. *J Hematol Oncol*. Mar 27 2011;4:12. doi:10.1186/1756-8722-4-12
28. Oliai C, Lanciano R, Sprandio B, et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. *J Radiat Oncol*. Mar 2013;2(1):63-70. doi:10.1007/s13566-012-0067-2

29. Onishi H, Araki T, Shirato H, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. *Cancer*. Oct 1 2004;101(7):1623-31. doi:10.1002/cncr.20539
30. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. *J Thorac Oncol*. Jul 2007;2(7 Suppl 3):S94-100. doi:10.1097/JTO.0b013e318074de34
31. Palma DA, Olson R, Harrow S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. *J Clin Oncol*. Sep 1 2020;38(25):2830-2838. doi:10.1200/jco.20.00818
32. Pollock BE. Stereotactic radiosurgery for intracranial meningiomas: indications and results. *Neurosurg Focus*. May 15 2003;14(5):e4. doi:10.3171/foc.2003.14.5.5
33. Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys*. Feb 1 2010;76(2):326-32. doi:10.1016/j.ijrobp.2009.09.042
34. Richling B, Killer M, Al-Schameri AR, Ritter L, Agic R, Krenn M. Therapy of brain arteriovenous malformations: multimodality treatment from a balanced standpoint. *Neurosurgery*. Nov 2006;59(5 Suppl 3):S148-57; discussion S3-13. doi:10.1227/01.Neu.0000237408.95785.64
35. Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. *Cancer*. Jun 1 2012;118(11):2962-70. doi:10.1002/cncr.26611
36. Scorsetti M, Alongi F, Filippi AR, et al. Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients. *Acta Oncol*. May 2012;51(5):618-23. doi:10.3109/0284186x.2011.652738
37. Lo SS. Stereotactic Radiosurgery. WebMD LLC. Updated December 19, 2018. Accessed December 7, 2021. <http://emedicine.medscape.com/article/1423298-overview>
38. Soffietti R, Cornu P, Delattre JY, et al. EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. *Eur J Neurol*. Jul 2006;13(7):674-81. doi:10.1111/j.1468-1331.2006.01506.x
39. Szeifert GT, Prasad D, Kamyrio T, Steiner M, Steiner LE. The role of the Gamma Knife in the management of cerebral astrocytomas. *Prog Neurol Surg*. 2007;20:150-163. doi:10.1159/000100102
40. Tipton KN, Sullivan N, Bruening W, et al. AHRQ Comparative Effectiveness Technical Briefs. *Stereotactic Body Radiation Therapy*. Agency for Healthcare Research and Quality (US); 2011.
41. Weil RS, Cohen JM, Portarena I, Brada M. Optimal dose of stereotactic radiosurgery for acoustic neuromas: A systematic review. *Br J Neurosurg*. Aug 2006;20(4):195-202. doi:10.1080/02688690600886108

Reviewed / Approved by NIA Clinical Guideline Committee

GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

Disclaimer: *National Imaging Associates, Inc. (NIA) authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Evolent Health LLC subsidiaries including, but not limited to, National Imaging Associates (“NIA”). The policies constitute only the reimbursement and coverage guidelines of NIA. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. NIA reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.*